GlassScriptPhysician profile
Michael Steven Lowley
NPI 1063894418
$2,697.60
in general payments reported to CMS, 2019-2025
17 companies · $844 in 2025
The $844 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.37 · 2020: $64.81 · 2021: $285 · 2022: $308 · 2023: $404 · 2024: $748 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $970.14 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $331.05 | 2023-2025 | Caplyta |
| Corium, LLC | $237.59 | 2022-2025 | Azstarys |
| Alkermes, INC. | $181.36 | 2020-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $162.24 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $135.03 | 2024 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $107.07 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $94.78 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $87.24 | 2025 | Fanapt |
| Tris Pharma INC | $65.69 | 2019-2025 | Dyanavel Xr |
| Lundbeck LLC | $60.46 | 2022-2024 | Rexulti |
| Iovance Biotherapeutics, INC. | $58.10 | 2025 | Amtagvi |
| Ironshore Pharmaceuticals INC. | $58.05 | 2024 | |
| Abbvie INC. | $50.43 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.06 | 2019-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $38.19 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $14.12 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.